Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Protease inhibitor-sparing regimens

Kimberly Y Smith1

  • 1Department of Medicine, Rush Medical College, Rush-Presbyterian-St. Luke's Medical Center, Chicago, USA. ksmith2@rush.edu

Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)
|August 29, 2003
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Durable Efficacy of Switching From a 3- or 4-Drug Tenofovir Alafenamide-Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine in the TANGO Study Through Week 196.

Journal of acquired immune deficiency syndromes (1999)·2024
Same author

Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2023
Same author

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2022
Same author

Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study.

The lancet. HIV·2021
Same author

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.

The lancet. HIV·2021
Same author

Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study.

Open forum infectious diseases·2021
Same journal

Cryptococcal antigen screening and preemptive therapy in patients initiating antiretroviral therapy in resource-limited settings: a proposed algorithm for clinical implementation.

Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)·2012
Same journal

Factors associated with false-positive results from fingerstick OraQuick ADVANCE rapid HIV 1/2 antibody test.

Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)·2012
Same journal

Greater acceptance of routine HIV testing (opt-out) by patients attending an infectious disease unit in Spain.

Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)·2012
Same journal

Once-daily nevirapine XR: a brief overview of the safety and efficacy of a new formulation.

Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)·2012
Same journal

Thalidomide-associated thrombosis in the treatment of HIV-associated severe aphthous disease: a case report and review of the literature.

Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)·2012
Same journal

Choosing sides: HIV health care practices among shared populations of HIV-positive Latinos living near the US-Mexico border.

Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)·2012
See all related articles